Metformin - The Gold Standard

Preface. Editors. Section 1 History and Heritage. Introduction by P Lefebvre. * Galegine and antidiabetic plants. * Discovery of metformin. * Introduction of metformin into clinical practice: the French innovation.* Metformin: a chemical perspective. * Pharmaceutical development of metformin. Section 2 Efficacy. Introduction by R A DeFronzo.* Defining the clinical utility of metformin: reflections from Scotland.* Metformin in combination. * Metformin in children and adolescents with type 2 diabetes. * Dose-related antihyperglycaemic efficacy of metformin. * Understanding the glucose-lowering actions of metformin. * Focus on metformin and body weight. * Insights into the effects of metformin on the lipid profile. Section 3 Cardiovascular Benefits. Introduction by R Holman.* Metformin and cardiovascular protection: lessons from the UK Prospective Diabetes Study.* Survival benefits of metformin in high-risk populations. * Mechanisms of vascular protection with metformin. Section 4 Health Outcomes. Introduction by C-Y Pan.* Defining the health economic benefits of metformin. * Impact of metformin on quality of life. Section 5 Safety. Introduction by N Hotta.* Tolerability of metformin. * Measures to improve the gastrointestinal tolerability of metformin. * Defining the risk of lactic acidosis. * Defining patient populations not indicated for metformin. Section 6 Guidelines. Introduction by D J Chisholm.* The role of metformin in setting treatment standards within management guidelines. Section 7 Future Indications. Introduction by J J Gagliardino.* The potential of metformin for diabetes prevention. * The role of metformin in polycystic ovary syndrome and infertility. * Potential of metformin in the management of insulin-resistant states.* The potential of metformin for the treatment of neoplastic disease.* Future role of metformin in healthcare therapy. Section 8 The metformin 50-year roll of honour. Index.